Detection of MYD88 L265P in Patients With Lymphoplasmacytic lymphoma/Waldenstrom Macroglobulinemia and Other B-cell non-Hodgkin Lymphomas

Blood Res. 2016 Sep;51(3):181-186. doi: 10.5045/br.2016.51.3.181. Epub 2016 Sep 23.


Background: Recent studies have identified a high prevalence of the MYD88 L265P mutation in lymphoplasmacytic lymphoma (LPL)/Waldenstrom macroglobulinemia (WM) cases, whereas low frequencies have been observed in other B cell non-Hodgkin lymphomas (NHLs).

Methods: We evaluated the sensitivity of the mutant enrichment 3'-modified oligonucleotide (MEMO)-PCR technique, a new detection method. We examined the MYD88 L265P mutation in a series of Korean patients with LPL/WM and other B cell NHLs in bone marrow aspirates, using the MEMO-PCR technique.

Results: The sensitivity of MEMO-PCR was estimated to be approximately 10-16.7%. MYD88 L265P was detected in 21 of 28 LPL cases (75%) and only three of 69 B cell NHL cases (4.3%).

Conclusion: Although MEMO-PCR had relatively low sensitivity, we confirmed the high prevalence of the MYD88 L265P mutation in Korean LPL patients. Our study suggests the diagnostic value of MYD88 L265P for differentiating B-cell NHLs.

Keywords: Aspirate; Lymphoplasmacytic lymphoma; MEMO-PCR; MYD88 L265P.